Crizotinib in Chinese Patients with ROS1-Rearranged Advanced Non‒Small-Cell Lung Cancer in Routine Clinical Practice.
Chang LiuHui YuJianhua ChangHaiquan ChenYuan LiWeixin ZhaoKuaile ZhaoZhengfei ZhuSi SunMin FanJialei WangPublished in: Targeted oncology (2020)
Crizotinib was effective and well tolerated in Chinese patients with ROS1-positive advanced NSCLC in real-world clinical practice. The progression sites and patterns, as well as treatments after first disease progression on crizotinib were diverse. Crizotinib beyond progressive disease and local therapy after failure of crizotinib treatment were feasible and effective in clinical practice.